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Background: Upper and lower airways allergic disease is currently considered unitarily.
Allergic inflammation in one site can extend to other sites of the respiratory tract.
Objective: To evaluate bronchial inflammation before and after allergen-specific nasal
challenge (ASNC) in rhinitic and asthmatic children, considering the different levels of
allergen exposure, i.e. summer (low) and winter (high).
Methods: Fourteen children with rhinitis and 15 with rhinitis and asthma, all
monosensitized to mites and 10 healthy controls were studied. Nasal IgE were measured
before ASNC in summer and in winter season. Nasal clinical score, eosinophil cationic
protein (ECP), nasal tryptase, bronchial clinical score, FEV1, PEF, sputum ECP, sputum
tryptase and exhaled nitric oxide (eNO) were evaluated before and after ASNC in summer
and winter season.
Results: Nasal scores significantly increased after ASNC in rhinitic and asthmatic children
in both seasons. Nasal IgE were significantly higher in summer compared to winter.
Bronchial symptoms, FEV1 and PEF showed no mean differences in rhinitic and asthmatic
children after ASNC, with an increase of bronchial symptoms and a decrease of FEV1 and
PEF occurring in 3/15 asthmatic children. In both groups nasal tryptase and ECP after ASNC
significantly increased in summer and winter, while sputum tryptase was undetectable
before or after ASNC in both groups. Sputum ECP and eNO at baseline were significantly
higher in patients than in controls (summer P ¼ 0:002, winter P ¼ 0:001). Sputum ECPPublished by Elsevier Ltd.
578 3621; fax: +39 075 573 3802.
(F. Marcucci).
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Lower airway inflammation before and after house dust mite nasal challenge 1601significantly increased after ASNC in 3/15 asthmatics in summer and in 11/15 in winter, as
well as in 3/14 rhinitics in summer and in 4/14 in winter. eNO significantly increased after
ASNC in 3/15 asthmatics in summer and in 10/15 in winter, and in 1/14 rhinitics in summer
and in 4/14 in winter. A significant median increase of sputum ECP (P ¼ 0:0007) and eNO
(P ¼ 0:0012) after ASNC in asthmatic and of eNO (P ¼ 0:013) in rhinitic children was also
found in winter.
Conclusions: Basal sputum ECP and eNO values, significantly higher before ASNC in rhinitic
patients compared to control subjects, confirm the inflammatory link of upper and lower
airways. The more frequent detection of inflammatory changes induced by ASNC in winter
suggests that allergen exposure favours the transfer of nasal inflammation to lower
airways.
& 2006 Published by Elsevier Ltd.Introduction
In the ARIA document, a position paper recently published
by WHO, a new classification of allergic rhinitis was
presented, which underlines the importance to consider
unitarily upper and lower airway disease.1
To support the relationship among different sites of the
respiratory tract in clinical conditions such as rhinosinusitis,
nasal poliposis and asthma, recent studies have demon-
strated that inflammation in one site can extend to other
sites of the respiratory tract.2,3
Analysis of blood samples and biopsies before and after
allergen segmental bronchial challenge (ASBC) in patients
with allergic rhinitis showed a significant eosinophil increase
in pulmonary tract biopsies distant from the site of
challenge and also in nasal epithelium.4,5
In a recent study on rhinitic patients monosensitized to
grass pollen out of season, a significant increase of
eosinophils, bronchial symptoms and a significant decrease
of FEV1 after allergen-specific nasal challenge (ASNC) was
observed.6 Moreover, several studies on adult rhinitic
patients have evidenced the presence of eosinophils after
ASNC in induced sputum.7–10 By contrast, another study
reported that nasal provocation with house dust mite did not
cause a decrease in FEV1 and concomitant wheezing in any
of the 15 rhinitic patients studied and only in 3/5 rhinitics
with a previous history of asthma.11 As to effect of anti-
inflammatory drugs, old studies,12–14 subsequently not
confirmed,15 showed that nasal corticosteroid therapy
achieved a reduction of bronchial symptoms and bronchial
hyperreactivity in patients with allergic rhinitis and asthma
to grass pollen.
In order to better understand the link between upper and
lower airways interaction, we evaluated bronchial inflam-
mation before and after ASNC in rhinitic and asthmatic
patients allergic to mite, in two different periods of low
(summer) and high (winter) allergen exposure.Material and methods
Fifteen children (age range 6–10 years) with rhinitis and
episodic asthma, 16 children with isolated rhinitis, all
monosensitized to dust mites, and 10 healthy non-atopic
controls were enrolled in the study. Diagnosis of asthma was
defined according to clinical history, clinical evaluationduring acute symptoms and FEV1 increase after inhaled
salbutamol. Asthma severity was classified as level 1
according to the GINA international guidelines.16 In both
groups the rhinitis was mild or moderate persistent,
according to ARIA document.1 Exclusion criteria included
local or systemic anti-inflammatory therapy (corticoster-
oids, DSCG, anti-leukotrienes, H1-anti-histamines) 2 months
prior to the study, specific immunotherapy, malformations or
chronic inflammatory diseases of airways and severe
systemic diseases. Both groups were instructed to enclose
mattresses and pillows in non-allergenic covers. During the
follow-up period patients could occasionally use oral
cetirizine for nasal symptoms and salbutamol and oral
metilprednisone for acute asthma. The study was approved
by the ethical committee of the University of Perugia and all
children’s parents gave their written informed consent.
In patients skin prick tests (SPT) and serum-specific IgE
were evaluated at the beginning (July) of the study. Nasal-
specific IgE were measured before ASNC in summer and in
winter season. Nasal and sputum tryptase, nasal and sputum
eosinophil cationic protein (ECP), nasal and bronchial
clinical scores, spirometry and exaled nitric oxide (eNO)
were evaluated in all patients before and after ASNC at the
beginning of the study in summer (low exposure) and at the
end in winter (high exposure). At baseline, nasal-specific
IgE, nasal and sputum tryptase, nasal and sputum ECP,
spirometry and eNO were evaluated also in the control
group. The coefficient of variation (CV) of sputum ECP and
eNO was evaluated twice in 120 asthmatic patients. In the
study patients tryptase, ECP and eNO after ASNC were
considered significant if they showed an increase of 50%
compared to basal values before ASNC.Skin prick test
SPT were performed with commercial glycerinated extracts
(Alk-Abello`, Lainate, Italy). The standard panel of allergens
included Phleum pratensis, Parietaria judaica, Olea euro-
paea, Dermatophagoides pteronyssinus, Alternaria tenuis,
cat, and dog epithelium, plus a positive (histamine 10mg/
mL) and a negative (normal saline) control. Wheals were
contoured with a soft pen and transferred onto sticky tape.
Skin reactivity was measured as the mean of the major
diameter of the wheal plus its orthogonal and graded
from 0 ¼ negative to ++++ ¼ highly positive, compared to
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considered the threshold for positivity.
Serum IgE
Specific serum IgE were measured with UNICAP SYSTEM IGE
FEIA method (Pharmacia, Uppsala, Sweden) for the same
allergens tested in SPT.
Nasal-specific IgE
Allergen-specific nasal IgE were measured using a previously
described method,17 modified as follows. Briefly, seven
allergen covalently coated paper disks plus a negative
control disk with chicken albumin (Sigma Aldrich, Milan,
Italy) were fixed on two sides of a plastic applicator (6 cm
length and 0.6 cm width). The allergens were the same used
for the prick test: Phleum pratensis, Parietaria judaica,
Olea europaea, D. ptironyssinus, A. tenuis, cat epithelium,
and dog epithelium Alk-Abello`). The applicator carrying the
disks was covered with a permeable polyamide monofila-
ment membrane (03-64/45-SEFAR Heiden, Switzerland). The
prepared device was inserted into a nostril of the subject
and left inside for 20min. The applicator was then removed
from the nostril, disks were put into a tube containing a
buffer solution (NaCl 0.9%, Tween 0.1% and NaN3 0.05%) and
stored at 4 1C. All assays were performed at the same time.
After 10min washing, the allergen-coated disks were
incubated for 30min with a biotinate goat IgG anti-human
IgE (VECTOR Laboratories, Peterborough, England) then
washed and incubated for 30min with Streptavidine-b-
galattosidase (Boehringer Ingelheim, Milan, Italia), washed
again and incubated for 10min with the fluorimetric
development kit (CAP System FEIA Pharmacia) and deter-
mined, as compared to a standard reference curve (CAP
System FEIA IgE Pharmacia) performed with goat IgG anti-
human IgE-coated paper disks (VECTOR Laboratories, Peter-
borough, England). Values equal or greater than 0.35 kU/L
were considered positive.
Nasal ECP and tryptase
Tryptase and ECP levels were determined by ELISA (UniCAP
Tryptase System FEIA and UniCAP ECP System FEIA,
Pharmacia) adapted for mucosal sampling.18 For ASNC
the measurement of tryptase was made 30min after and
that of ECP 24 h after. Briefly, the sponges of the CAP
System, coated with anti-tryptase or anti-ECP antibodies,
were washed with physiologic solution and then mounted on
an appropriate plastic stick and fixed by a permeable
envelope. The plastic stick carrying the sponges was then
inserted into a nostril and incubated in situ for 10min fixed
with a tape externally on the nose. The sponges were then
removed and frozen at 20 1C in buffered (NaCl plus NaN3
0.1%) vials. At the end of the trial, all sponges were washed
3 times for 10min with NaCl 0.9% and Tween 0.1%,
reinserted into CAPs and run at the same time with Unicap
System FEIA Pharmacia. The concentration of tryptase and
ECP was expressed in mg/L according to a calibration
curve.19Sputum ECP and tryptase
Sputum was induced by having the subject inhaled hyper-
tonic saline solution 4%.20 Briefly, prior to sputum induction,
all subjects inhaled a b2-agonist to avoid hypertonic saline
solution-induced bronchoconstriction. The subjects were
asked to rinse their mouth and throat every 5min and then
to try to cough sputum into a sterile plastic container. The
nebulization was continued for at least 10min and stopped
after 20min or earlier if a X2mL sputum sample of good
quality was obtained. The collected sample was weighted,
mixed with an equal volume of a solution containing
dithiothreitol (DTT) 0.1%, and then centrifuged at 2000g
for 20min. The supernatant was aspirated and ECP
and tryptase were measured in duplicate using the
UniCAP Tryptase System FEIA and UniCAP ECP System FEIA
(Pharmacia).Spirometry
Spirometry was performed with a Microloop Micro Medical
spirometer (Micro Medical, Rochester, England). The sub-
jects were asked to perform subsequently three times a
maximum expiratory effort immediately following a max-
imum inspiration, with a rapid start, and the best FEV1 was
registered.Exhaled NO
Exhaled NO was measured using a chemoluminescence NO
analyzer (Eco Physics CLD 77 AM, Eco Physics, Switzerland)
with a detection limit of 0.02 parts per million (ppm). The
zero signal was calibrated with an air filter (Sievers AFL
01410-01) and the measurement scale was calibrated with
a gas containing 100 ppm of NO in nitrogen (MESSER,
Turin, Italy). Subjects at rest, sitting down and wearing a
mouthpiece, performed a single exhalation from total
lung capacity without breath-holding and were encouraged
to maintain a constant expiration throughout the
manoeuver.ASNC, nasal and bronchial clinical scores
ASNC was performed by spraying the vehicle into a nostril
followed by increasing concentrations of house dust mite
extract: 2, 4, and 8 BU/mL (Alk-Abello`). These concentra-
tions correspond respectively to about 0.016, 0.032, and
0.064 mg per puff of the major allergen.
Nasal symptoms were evaluated attributing an arbitrary
score to itching, sneezing, rhinorrhea and blockage as
follows: 0 ¼ absent, 1 ¼ mild, 2 ¼ moderate, 3 ¼ severe.
Asthma symptoms considered were: coughing (asthma
related), wheezing and breathing difficulty. Severity of
asthma symptoms was evaluated attributing an arbitrary
score to each symptom as follows: 0 ¼ absent, 1 ¼ mild,
2 ¼ moderate, 3 ¼ severe. A total score increase of at least
3, between basal and after ASNC values, was used to define
the threshold dose for the positive challenge.
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Sputum ECP and eNO were evaluated twice in 120 patients
and within-subjects standard deviation was also used for
computation of the CV. The Wilcoxon signed rank test for
paired data was used to detect differences between basal
and after-ASNC values of nasal and sputum tryptase, nasal
and sputum ECP and eNO. Mann-Whitney test was used for
intergroup analysis of the same values and for basal IgE
values, evaluated during maximal and minimal exposureTable 1 Normal values in 10 non atopic controls.
Non-atopic controls Nasal IgE (kU/L)
Mean o0.35
Range o0.35o 0.35
Non-atopic controls Sputum tryptase (mcg/L)
Mean o1
Range o1o1
Table 2 Clinical scores, FEV1 and PEF.
Season Baseline Aft
Nasal clinical scores
Summer
Rhinitis 2.5672.92 6.7
Asthma 2.1872.13 6.6
Winter
Rhinitis 1.5672.37 5.6
Asthma 2.1872.67 5.6
Bronchial clinical scores
Summer
Rhinitis 1.1371.45 2.4
Asthma 2.2872.56 3.0
Winter
Rhinitis 2.0972.47 2.9
Asthma 2.5472.45 4.2
FEV1
Summer
Rhinitis 9173.3 9
Asthma 88.173.2 8
Winter
Rhinitis 89.775.2 87.
Asthma 88.274.3 87.
PEF
Summer
Rhinitis 87.476.8 92.
Asthma 8674.6 86.
Winter
Rhinitis 88.273.9 86.
Asthma 87.473.9 85.period in the two groups. A P-value lower than 0.05 was
considered significant.
Results
In non-atopic healthy controls nasal-specific IgE and tryptase
were negative, nasal ECP showed a median value of
7.6mcg/L (rangeo2–22) (Table 1). In these children sputum
tryptase was negative, sputum ECP had a median value of
5.31mcg/L (range o2–11.25) and eNO showed a median ofNasal tryptase (mcg/L) Nasal ECP (mcg/L)
o1 7.6
o1o1 o222
Sputum ECP (mcg/L) eNO (ppm)
5.31 8.47
o211.25 3.8816.42
er challenge Baseline vs. after (P-value)
873.49 0.014
373.20 0.005
773.53 0.012
573.67 0.027
772.13 NS
373.34 NS
873.32 NS
573.46 NS
072.7 NS
873.5 NS
672.3 NS
372.9 NS
174.8 NS
973.4 NS
774.9 NS
372.4 NS
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uated twice in 120 patients showed a CV of 33.6%; eNO
evaluated twice in 120 patients showed a CV of 24%. For the
aim of our study, tryptase, ECP and eNO were considered
significant after ASNC if they showed an increase 450%
compared to values before ASNC. Two rhinitic children were
not evaluated, the first because he did not complete the
study, the second because had persistent high values of
sputum ECP (4200mcg/L) with no variation in the differentTable 3 Nasal tryptase, ECP and IgE.
Season Baseline
Nasal tryptase (mcg/L)
Summer
Rhinitis 3.5076.88
Asthma 19.25729.48
Winter
Rhinitis 12.03726.75
Asthma 24.73739.29
Nasal ECP (mcg/L)
Summer
Rhinitis 20.33725.64
Asthma 47.59762.05
Winter
Rhinitis 17.44735.33
Asthma 45.9751.78
HDM nasal-specific IgE (KU/l)
Summer
Rhinitis 1.2872.15
Asthma 1.8873.25
Winter
Rhinitis 6.1478.16
Asthma 3.1673.39
0
20
40
60
80
100
120
q1
min
median
max
q3
1
1
Sputum ECP
P=0.001 p=0.001 p=0.001
P=0.002
Controls Asthmatics Rhinitics
mcg/l Summer Winter Summer Winter
Figure 1 Comparison between baseline values ofevaluations. Thus, the number of studied children with
rhinitis was 14.
All patients reported occasional ingestions of oral
cetirizine during winter. 12/15 asthmatic children occasion-
ally took salbutamol and 5/15 oral methylprednisolone
(mean assumption: 35mg/month) in the last 2 months of
winter. 13/15 asthmatics and 5/14 rhinitics reported to have
used enclosed mattresses and pillows, as we suggested at
the beginning of the study.After challenge Basel vs. after (P-value)
40.02761.29 0.017
28.67736.59 0.021
57.77770.50 0.012
51.74756.25 0.004
77.50784.63 0.028
95.34768.68 0.003
73.88777.73 0.011
112.35768.07 0.021
Summer vs. winter
0.038
0.033
0
20
40
60
80
00
20
q1
min
median
max
q3
eNO
p=0.001
p=0.001
p=0.002
P=0.002
Controls Asthmatics Rhinitics
ppm Summer Winter Summer Winter
sputum ECP and eNO in patients and controls.
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showed a significant increase of nasal symptoms after ASNC
in summer (rhinitics: P ¼ 0:014, asthmatics: P ¼ 0:005)
and in winter (rhinitics: P ¼ 0:012; asthmatics: P ¼ 0:027)
(Table 2).
In rhinitic patients symptoms of bronchial obstruction and
significant decrease of FEV1 or PEF after ASNC were not
observed in both periods (Table 2). Three of 15 asthmatic
patients showed symptoms of bronchial obstruction and a
decrease of FEV1 after ASNC in winter season, but in these
patients a significant mean increase of bronchial symptoms
or a decrease of spirometric values after ASNC was not
apparent (Table 2). House dust mite nasal-specific IgE
showed a significant increase in winter when compared to
summer both in rhinitic (P ¼ 0:038) and in asthmatic
(P ¼ 0:033) patients (Table 3).
Nasal tryptase in rhinitic and asthmatic patients was
higher than in healthy controls and showed a significant
increase after ASNC in summer (rhinitic P ¼ 0:017, asth-
matic P ¼ 0:021) and in winter (rhinitic P ¼ 0:012, asthmatic
P ¼ 0:004) (Table 3).
Nasal ECP in rhinitic and asthmatic patients was more
elevated compared to healthy controls and showed a
significant increase after ASNC in summer (rhinitic
P ¼ 0:028, asthmatic P ¼ 0:003) and in winter (rhinitic
P ¼ 0:011, asthmatic P ¼ 0:021) (Table 3).1
0
50
100
150
200
0
50
100
150
200
1
0
50
100
150
200
0
50
100
150
200
ASTHMATICS Sputum ECP
Summer Winter
mcg/l Before After ASNC Before After ASNC
RHINITICS Sputum ECP
Summer Winter
mcg/l Before After ASNC Before After ASNC p
Figure 2 Sputum ECP and eNO in asthmatic and rhinitics in both pe
dotted line ¼ increase o50%.Sputum tryptase before and after ASNC was not detect-
able in most cases and was not evaluated (data not
reported).
The median basal values of sputum ECP in rhinitic patients
was significantly more elevated than in control subjects in
winter (P ¼ 0:001) and in summer (P ¼ 0:001) (Fig. 1). In
these children sputum ECP after ASNC showed a significant
increase (450%) in 3/14 cases in summer and in 4/14 in
winter, when compared to values before ASNC (Fig. 2).
In asthmatic children, basal sputum ECP was significantly
higher than in control subjects in winter (P ¼ 0:001) and in
summer (P ¼ 0:002), but not significantly different from
rhinitic patients (Fig. 1). In these asthmatic children sputum
ECP showed a significant increase after ASNC only in 3/15
cases in summer and in 10/15 cases in winter (Fig. 2), but the
global difference in these two groups was not significant.
In rhinitic children the median basal value of eNO was
higher than in control subjects in winter (P ¼ 0:001) and in
summer (P ¼ 0:002) (Fig. 1). In these children eNO showed a
significant increase (450%) after ASNC in 1/14 cases in
summer and in 4/14 cases in winter (Fig. 2).
In asthmatic children basal eNO was higher than in control
subjects in summer (P ¼ 0:002) and in winter (P ¼ 0:001)
period (Fig. 1). In these children eNO showed a significant
increase after ASNC in 3/15 cases in summer and in 10/15 in
winter (Fig. 2).0
20
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60
80
00
0
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80
100
0
20
40
60
80
00
0
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80
100
exhaled NO
Summer Winter
ppm Before After ASNC Before After ASNC
exhaled NO
Summer Winter
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riods, before and after ASNC. Continuous line ¼ increaseX50%,
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Figure 3 Median value of sputum ECP and eNO in asthmatic and rhinitic groups.
F. Marcucci et al.1606The median increase of sputum ECP and eNO after ASNC
was significant in asthmatic group in winter season
(respectively P ¼ 0:0007 and P ¼ 0:0012) (Fig. 3). In rhinitic
group a significant median increase of eNO (P ¼ 0:013) after
ASNC was also observed in winter (Fig. 3).Discussion
In recent years several mechanisms have been suggested to
support the clinical evidence of a link between upper and
lower airways.2,3 Until now the most reliable mechanism is
that allergic inflammation, which originates in a site of the
respiratory tract, through bone marrow stimulation and
cellular homing, is transferred to a different site of the
respiratory tract.4,5 The aim of our study was to evaluate
bronchial inflammation before and after ASNC in asthmatic
and rhinitic children monosensitized to mites in two different
periods of low (summer) and high (winter) allergen exposure.
Our rhinitic and asthmatic patients showed before ASNC
in both seasons a median basal sputum ECP value signifi-
cantly higher than in control subjects. The basal sputum ECP
data were also confirmed by median basal eNO which was
more elevated in patients compared to control subjects
(Fig. 1). These results, observed also in rhinitic children,
support the concept of the inflammatory link between upper
and lower airways. Similarly to a previous study21 asignificant difference of basal sputum ECP and eNO between
rhinitic and asthmatic patients (all with episodic asthma)
was not observed. This may be also due to the different
compliance to environmental measures and use of oral
corticosteroid therapy we observed. In fact, in 13/15
asthmatics but only in 5/14 rhinitics the enclosing of
mattresses and pillows was performed and 5/15 asthmatics
reported occasional oral methylprednisolone therapy. Dif-
ferently from a previous study conducted in patients allergic
to grass pollen out of season exposure,6 our young patients
monosensitized to mites showed after ASNC a significant
increase of sputum ECP and eNO, more frequent in winter
compared to summer season (Fig. 2). These data were also
confirmed by the results of the significant median increase
of sputum ECP (P ¼ 0:0007) and eNO (P ¼ 0:0012) after ASNC
in the group of asthmatic patients in winter and of eNO
(0.013) in the group of rhinitic patients in the same season
(Fig. 3). A higher exposure to mites during winter, described
in previous studies,21,22 was indirectly confirmed in our
study by the significant increase of nasal IgE in this period,
compared to summer values (Table 3). Considering all these
data, differently from other studies, we did not evidence
significant variations in these mediators in the lower
exposure period.
The difference between our data and Braunstahl study6
may be explained by the different population enrolled in the
two studies. In fact, we studied children with mild or
ARTICLE IN PRESS
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classified as GINA level 1, asthma, between 6 and 10 years of
age, in which the link between nasal and bronchial
inflammation is probably lower compared to adult patients
with a long-lasting disease. Braunstahl patients were adults
with at least 2 years of symptoms due to grass pollen. This
hypothesis of a lower inflammation level in our children is
supported by clinical scores and respiratory functional
values observed in our patients before and after ASNC. In
fact, unlike the above study,6 we found symptoms of
bronchial obstruction and variations in spirometric values
after ASNC only in 3/15 asthmatic children. Our data are in
agreement with three previous studies in which rhinitic
patients did not show bronchial symptoms or spirometric
changes after ASNC.23–25 Furthermore, in a recent report
nasal challenge with house dust mite did not elicit either a
fall in FEV1 or wheezing in any of the 15 rhinitic patients
studied and only in 3/5 rhinitics with a previous history of
asthma.11 We should consider that the occurrence of
wheezing and a fall of FEV1 in rhinitic patients after ASNC
in the study by Braunstahl et al. on adults could be due to
the presence of an undiagnosed asthma condition, as
supposed by the same authors.6
In a recent study, performed in adult patients allergic to
mites, an increase of sputum ECP after bronchial allergen
challenge was observed in asthmatic and in rhinitic subjects,
but a significant increase of neutrophil, interleukin-8 (IL-8)
and mieloperoxidase (MPO) was evident only in asthmatic
patients.21 These findings suggest that such specific im-
munologic modifications in lower airways predispose to the
development or persistence of asthmatic symptoms in
allergic subjects.21 Our data following ASNC, as well as the
absence of bronchial symptoms and lack of increase of
sputum ECP and eNO in more allergic patients, should be
explained with the hypothesis that the implication of
neutrophil inflammation, reported in severe asthma,26,27 is
likely to be negligible in children with intermittent asthma.
More asthmatic children in fact showed a further recovery of
bronchial symptoms, that might be due to spontaneous
immunological tolerance to inhaled antigen.28
In conclusion, the results of basal sputum ECP and eNO
before ASNC, significantly more elevated in asthmatic and
also in rhinitic patients compared to control subjects, confirm
the inflammatory link of upper and lower airways. Differently
from previous studies in adults, in our children the bronchial
inflammation after ASNC is more apparent in winter. This
observation, concerning not only the asthmatic but also some
rhinitic children, support the concept that specific bronchial
immunologic modifications,21 induced by chronic disease, are
needed to transfer nasal inflammation following ASNC to
lower airways. The increase in sputum ECP and eNO after
ASNC in rhinitic children without wheezing could suggest the
use of these mediators as positive predictive markers of
evolution towards asthma, but further prospective studies
are necessary to confirm this hypothesis.
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